MA41058B1 - Capsules molles de calcifédiol - Google Patents

Capsules molles de calcifédiol

Info

Publication number
MA41058B1
MA41058B1 MA41058A MA41058A MA41058B1 MA 41058 B1 MA41058 B1 MA 41058B1 MA 41058 A MA41058 A MA 41058A MA 41058 A MA41058 A MA 41058A MA 41058 B1 MA41058 B1 MA 41058B1
Authority
MA
Morocco
Prior art keywords
calcifediol
soft capsules
capsules
soft
hypophosphatemia
Prior art date
Application number
MA41058A
Other languages
English (en)
Inventor
Negre Josep María Suñé
Azpitarte Ignacio Ortega
Arenal Barrios Pepa Del
Herrero Gonzalo Hernández
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41058(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of MA41058B1 publication Critical patent/MA41058B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Lubricants (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Paints Or Removers (AREA)

Abstract

La présente invention concerne des capsules souples de calcifédiol, leur utilisation pour le traitement ou la prévention de maladies liées à la carence en vitamine d telles que la déminéralisation, l'hypocalcémie et l'hypophosphatémie, l'ostéodystrophie rénale, le rachitisme, l'ostéoporose, l'ostéopénie, l'ostéoarthrite, l'ostéoarthrose, l'ostéomalacie, l'hypoparathyroïdisme, et la maladie intestinale inflammatoire ainsi que leur procédé de fabrication.
MA41058A 2015-02-06 2016-02-05 Capsules molles de calcifédiol MA41058B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382042.8A EP3053598A1 (fr) 2015-02-06 2015-02-06 Capsules molles de calcifédiol
PCT/EP2016/052458 WO2016124724A1 (fr) 2015-02-06 2016-02-05 Capsules souples de calcifédiol

Publications (1)

Publication Number Publication Date
MA41058B1 true MA41058B1 (fr) 2020-05-29

Family

ID=52462260

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41058A MA41058B1 (fr) 2015-02-06 2016-02-05 Capsules molles de calcifédiol
MA052507A MA52507A (fr) 2015-02-06 2016-02-05 Capsules molles de calcifédiol

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA052507A MA52507A (fr) 2015-02-06 2016-02-05 Capsules molles de calcifédiol

Country Status (30)

Country Link
US (1) US10525018B2 (fr)
EP (3) EP3053598A1 (fr)
JP (2) JP6427270B2 (fr)
KR (1) KR101971384B1 (fr)
CN (2) CN106999441B (fr)
AU (1) AU2016214336B2 (fr)
BR (1) BR112017010657B1 (fr)
CA (1) CA2967170C (fr)
CL (1) CL2017001335A1 (fr)
CO (1) CO2017004545A2 (fr)
CY (1) CY1122976T1 (fr)
DK (2) DK3204047T3 (fr)
EA (1) EA034821B1 (fr)
ES (2) ES2941385T3 (fr)
HR (1) HRP20200859T1 (fr)
HU (1) HUE050133T2 (fr)
LT (1) LT3204047T (fr)
MA (2) MA41058B1 (fr)
MD (1) MD3204047T2 (fr)
ME (1) ME03739B (fr)
MX (1) MX367999B (fr)
MY (1) MY189432A (fr)
PE (1) PE20170911A1 (fr)
PH (1) PH12017501350A1 (fr)
PL (1) PL3204047T3 (fr)
PT (1) PT3204047T (fr)
RS (2) RS64166B1 (fr)
SI (1) SI3204047T1 (fr)
WO (1) WO2016124724A1 (fr)
ZA (1) ZA201703444B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3053598A1 (fr) 2015-02-06 2016-08-10 Faes Farma, S.A. Capsules molles de calcifédiol
CN108542908A (zh) * 2018-06-08 2018-09-18 唐飞 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
WO2021011538A1 (fr) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Formes galéniques capsules, leurs procédés de préparation et leurs procédés d'utilisation
CN113559079B (zh) * 2020-04-28 2023-10-20 江苏恒瑞医药股份有限公司 一种软胶囊及其制备方法和用途
WO2022103634A1 (fr) * 2020-11-16 2022-05-19 Orcosa Inc. Utilisation améliorée de cannabinoïdes dans le traitement de l'épilepsie
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022224001A1 (fr) 2021-04-22 2022-10-27 Faes Farma, S.A. Schéma posologique universel de 25-hydroxy vitamine d3
CN114159402A (zh) * 2021-12-21 2022-03-11 湖州展望天明药业有限公司 一种不透明植物胶囊及其制备方法
CN114712505B (zh) * 2022-03-10 2023-09-05 南方医科大学南方医院 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用
CN116270520A (zh) * 2023-03-03 2023-06-23 正大制药（青岛）有限公司 一种维生素d胶囊型滴剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532126A (en) 1982-05-07 1985-07-30 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS6335411A (ja) 1986-07-29 1988-02-16 Tonen Sekiyukagaku Kk 高純度合成石英の製造方法
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
JPH054925A (ja) 1991-06-27 1993-01-14 Teikoku Chem Ind Corp Ltd アルフアカルシドール軟カプセル製剤
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
ATE484283T1 (de) * 1999-08-31 2010-10-15 Chugai Pharmaceutical Co Ltd Weichkapseln
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
CA2469119A1 (fr) 2001-12-03 2003-06-12 Novacea, Inc. Compositions pharmaceutiques comprenant des composes actifs de vitamine d
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US20030158264A1 (en) * 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
AU2003230191A1 (en) 2002-02-20 2003-09-09 Strides Arcolab Limited Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
CA2480814A1 (fr) 2002-04-05 2003-10-23 Merck & Co., Inc. Procede d'inhibition de resorption osseuse a l'aide d'une formulation a base d'alendronate et de vitamine d
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
AU2004203436A1 (en) 2003-09-24 2005-04-14 Bioxell Spa Compound and use in treatment
US20050142185A1 (en) 2003-12-29 2005-06-30 Beleno Alfredo B. Softgel formulations of bisphosphonates bone resorption inhibitors
US20050152969A1 (en) 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
US20050175686A1 (en) 2004-02-11 2005-08-11 Ramachandran Radhakrishnan Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
WO2005120459A2 (fr) 2004-06-07 2005-12-22 Strides Arcolab Limited Composition pharmaceutique renfermant une solution stable et claire de medicament anti-inflammatoire contenue dans une capsule gelatineuse molle, et procede de production correspondant
EP1928471A2 (fr) 2005-09-26 2008-06-11 Novacea, Inc. Prevention et traitement des troubles gastro-intestinaux et de la vessie lies a la chimiotherapie ou a la radio therapie a l'aide de composes actifs de vitamine d
US20070098819A1 (en) * 2005-11-02 2007-05-03 Susan Thys-Jacobs Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks
US8426391B2 (en) * 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US8501717B2 (en) * 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
DK3342405T3 (da) * 2007-04-25 2019-11-11 Opko Ireland Global Holdings Ltd Kontrolleret frigivelse af 25-hydroxyvitamin d
SI2321273T1 (sl) 2008-07-24 2015-03-31 Wisconsin Alumni Research Foundation Enkrat tedensko dajanje 25-hidroksi-vitamina D3 za vzdrževanje povišane stacionarne farmakokinetične krvne koncentracije
MX2011006307A (es) 2008-12-15 2011-10-14 Banner Pharmacaps Inc Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
WO2010117873A2 (fr) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Solutions de progestérone à plus grande biodisponibilité
WO2012047098A1 (fr) 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Vitamine liposoluble encapsulée
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3053598A1 (fr) 2015-02-06 2016-08-10 Faes Farma, S.A. Capsules molles de calcifédiol

Also Published As

Publication number Publication date
ES2941385T3 (es) 2023-05-22
EA034821B1 (ru) 2020-03-25
CN106999441B (zh) 2020-11-24
PT3204047T (pt) 2020-06-05
EP3204047A1 (fr) 2017-08-16
PE20170911A1 (es) 2017-07-12
ES2738642T3 (es) 2020-11-06
MY189432A (en) 2022-02-11
CY1122976T1 (el) 2021-10-29
EP3689380A1 (fr) 2020-08-05
DK3204047T3 (da) 2020-06-02
AU2016214336A1 (en) 2017-05-25
CA2967170C (fr) 2018-06-05
RS64166B1 (sr) 2023-05-31
PH12017501350A1 (en) 2017-12-18
CL2017001335A1 (es) 2018-01-19
JP2017536358A (ja) 2017-12-07
CO2017004545A2 (es) 2017-08-31
US20170348249A1 (en) 2017-12-07
MD3204047T2 (ro) 2020-06-30
EP3204047B1 (fr) 2020-05-27
WO2016124724A1 (fr) 2016-08-11
EP3053598A1 (fr) 2016-08-10
KR101971384B1 (ko) 2019-04-22
MX367999B (es) 2019-09-12
CN112843014A (zh) 2021-05-28
EP3689380B1 (fr) 2023-03-15
CN106999441A (zh) 2017-08-01
MX2017006272A (es) 2017-08-14
KR20170093123A (ko) 2017-08-14
BR112017010657B1 (pt) 2022-10-11
US10525018B2 (en) 2020-01-07
HRP20200859T1 (hr) 2020-08-21
ME03739B (fr) 2021-01-20
CA2967170A1 (fr) 2016-08-11
MA52507A (fr) 2021-03-10
BR112017010657A2 (pt) 2018-02-14
EA201791097A1 (ru) 2017-08-31
ZA201703444B (en) 2019-09-25
SI3204047T1 (sl) 2020-07-31
ES2738642T1 (es) 2020-01-24
DK3689380T3 (da) 2023-05-22
JP6697779B2 (ja) 2020-05-27
HUE050133T2 (hu) 2020-11-30
JP6427270B2 (ja) 2018-11-21
KR101971384B9 (ko) 2022-07-25
RS60467B1 (sr) 2020-07-31
PL3204047T3 (pl) 2020-08-24
LT3204047T (lt) 2020-07-10
AU2016214336B2 (en) 2017-10-19
JP2018184458A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
MA41058B1 (fr) Capsules molles de calcifédiol
MA38633A1 (fr) Système à lots multiples pour la préparation d'une solution de bicarbonate de calcium convenant à la reminéralisation d'eau dessalée et d'eau naturellement douce
MA42376B1 (fr) Dérivés d'oxopyridine substitués
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41013A (fr) Compositions comprenant des souches bactériennes
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA40893A (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MA39342A1 (fr) Anticorps il -21
WO2015059463A3 (fr) Bêta-caténine
FR3007039B1 (fr) Procede d'obtention d'un extrait de plante et compositions associees
FR3070263B1 (fr) Composition pour son utilisation dans le traitement et/ou la prevention de l’infertilite
RU2014138694A (ru) Состав для стимуляции метаболических процессов, системы иммунитета, профилактики заболеваний диареей
FR3057455B1 (fr) Equipement pour le traitement d'une fracture par haubanage, par exemple d'une fracture de l'olecrane ou de la rotule
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
TH174557B (th) สารประกอบไบไซคลิคซึ่งถูกแทนที่
MA41104A (fr) Compositions comprenant des souches bactériennes
MA41059A (fr) Compositions comprenant des souches bactériennes
MA45609A (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite
MA46437B1 (fr) Agonistes de ppar, composés, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci.
MA46307A1 (fr) Composition et procédés pour moduler l'expression du facteur b du complément
MA38491A1 (fr) Dérivé dihydropyridazine-3,5-dione